IDYA moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 89 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The 10-day moving average for IDYA crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for IDYA entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IDYA's RSI Oscillator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 219 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.846) is normal, around the industry mean (3.009). P/E Ratio (-18.417) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
On October 20, 2026, the Stochastic Oscillator for XNCR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 51 instances where the indicator left the oversold zone. In 38 of the 51 cases the stock moved higher in the following days. This puts the odds of a move higher at over 75%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 50 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +9.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 188 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
XNCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
XNCR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XNCR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.685) is normal, around the industry mean (3.009). P/E Ratio (-11.546) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IDYA | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | |
SMR RATING 1..100 | 94 | 97 | |
PRICE GROWTH RATING 1..100 | 58 | 37 | |
P/E GROWTH RATING 1..100 | 38 | 78 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDYA's Valuation (11) in the null industry is in the same range as XNCR (20) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XNCR’s over the last 12 months.
IDYA's Profit vs Risk Rating (82) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XNCR’s over the last 12 months.
IDYA's SMR Rating (94) in the null industry is in the same range as XNCR (97) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XNCR’s over the last 12 months.
XNCR's Price Growth Rating (37) in the Biotechnology industry is in the same range as IDYA (58) in the null industry. This means that XNCR’s stock grew similarly to IDYA’s over the last 12 months.
IDYA's P/E Growth Rating (38) in the null industry is somewhat better than the same rating for XNCR (78) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than XNCR’s over the last 12 months.
| IDYA | XNCR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | N/A |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 66% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 73% |
| Advances ODDS (%) | 1 day ago 76% | 1 day ago 74% |
| Declines ODDS (%) | 5 days ago 76% | 7 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 69% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDYA’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDYA’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).
IDYA (@Biotechnology) experienced а +3.21% price change this week, while XNCR (@Biotechnology) price change was +6.04% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
IDYA is expected to report earnings on Nov 03, 2026.
XNCR is expected to report earnings on Nov 04, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SKYU | 50.94 | 1.27 | +2.56% |
| ProShares Ultra Nasdaq Cloud Computing ETF (SKYU) | |||
| GMF | 151.19 | 0.55 | +0.36% |
| State Street SPDR S&P Emerging Asia Pacific ETF (GMF) | |||
| CPSR | 26.27 | 0.01 | +0.04% |
| Calamos S&P 500 Structured Alt Protection ETF - March | |||
| CSHI | 49.62 | 0.01 | +0.02% |
| NEOS Enhanced Income 1-3 Month T-Bill ETF (CSHI) | |||
| CHPX | 89.44 | -0.21 | -0.24% |
| Global X AI Semiconductor & Quantum ETF (CHPX) | |||